Biopharma PSP development report: key takeaways point to future trends
AI-translated from the Chinese original · editorially reviewed
The biopharmaceutical industry is in transformation, especially in the area of Patient Support Programs (PSP). Based on a survey of 150 biopharma executives and advisors conducted by CardinoHealth in partnership with BioPharma Dive, three key conclusions emerge that highlight how rapidly PSPs are developing across the pharmaceutical industry today.
1: Deciding whom to help comes first
Nearly half of respondents named determining PSP eligibility as one of the most important goals. This shows pharmaceutical companies are increasingly focused on making sure PSPs truly reach the patients who need them. In the past, a PSP might simply have aimed to broaden coverage; the emphasis now is on special cases and individualized needs. That means companies must identify more precisely which patients can benefit from a PSP so that resources are allocated appropriately. The shift means the PSP is no longer just an adjunct to the prescription — it is a comprehensive program built around patient needs.
2: Data collection is critical
The survey notes that PSP data collection has expanded from patient-side content alone to integration with provider-side workflows. This gives pharmaceutical companies a fuller, richer picture of the patient journey — information essential to delivering better support. Automated data collection technology is also becoming increasingly important to ensure accuracy and timeliness. This will improve PSP performance and keep programs aligned with patient needs. PSPs therefore need not only rich data, but modern technology to put that information to effective use.
3: The importance of relay services
PSP services act as a relay station along the patient journey, giving biopharma companies valuable internal perspective and delivering value beyond the medicine itself. One trend ahead is greater patient participation in shaping PSP service content, making programs more personalized and closer to real needs. It also means biopharma companies must become more flexible and open to patient involvement and contribution. Relay services are not just about providing information — they build interaction and trust between patients and pharmaceutical companies.
In short, the biopharmaceutical industry is transforming, and Patient Support Programs (PSP) are one of the key drivers. Truly helping the patients who need it depends on eligibility determination, rich data collection, and the delivery of relay services. This shift affects not only pharmaceutical companies but will have a profound impact on public health and quality of life. Companies therefore need more innovative, individualized approaches to ensure PSPs meet patient needs to the fullest — improving treatment outcomes and quality of life while staying attentive to patients' needs and expectations. The transformation is both a challenge and an opportunity to care for and support our health more deeply.
Evie Wang, Director, Media-WIND Health Strategies
evie.wang@media-wind.com.tw
References